Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric and adult patients.
## Primary Indications
Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability, not to exceed maximum daily dose.
* **Maintenance:** Usual maintenance dose is 10-20 mg twice daily.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing
* **Ages 2 to <10 years:**
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5-5 mg every week based on clinical response and tolerability, not to exceed maximum daily dose.
* **Maintenance:** Usual maintenance dose is 5-10 mg twice daily.
* **Maximum Daily Dose:** 10 mg twice daily (20 mg/day).
* **Ages 10 years and older:**
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week based on clinical response and tolerability, not to exceed maximum daily dose.
* **Maintenance:** Usual maintenance dose is 10-20 mg twice daily.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but lower doses may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established.
* **Concomitant Medications:** Consider potential interactions (see Key Drug Interactions).
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Acute narrow-angle glaucoma.
## Adverse Effects
**Common:** Somnolence, sedation, ataxia, fatigue, decreased appetite, constipation, aggression, irritability, difficulty with coordination.
**Serious:** Suicidal behavior or ideation, respiratory depression, severe dermatologic reactions (e.g., Stevens-Johnson syndrome), withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and potentially fatal outcomes. Monitor closely.
* **CYP3A4/CYP2C19 Inhibitors/Inducers:** Clobazam is metabolized by CYP3A4 and CYP2C19. Inhibitors may increase clobazam levels, inducers may decrease them. Specific interactions are complex and may require dose adjustments.
* **Other Anticonvulsants:** Monitor for additive CNS effects and potential changes in efficacy.
## Monitoring
* Monitor for effectiveness (seizure frequency).
* Monitor for adverse effects, especially somnolence, sedation, and signs of withdrawal.
* Monitor for suicidal behavior or ideation.
* Monitor for signs of potential drug interactions.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy.
* Discontinuation should be gradual to avoid withdrawal symptoms.
* Clobazam is a Schedule IV controlled substance.
* Risk of serious skin reactions exists. Advise patients to seek immediate medical attention for any new rash.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and your healthcare provider for any medical decisions.
